DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

Completed

Conditions: Hodgkin's Disease

First Posted Date: 2005-09-14

Last Posted Date: 2012-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00165438

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma
Gliosarcoma
Malignant Gliomas

First Posted Date: 2005-09-14

Last Posted Date: 2010-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00165477

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients

Not Applicable

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-12-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165386

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

Completed

Conditions: Endometrial Carcinoma
Cervix Cancer
Carcinoma of the Uterus

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00165126

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Prolonged Daily Temozolomide for Low-Grade Glioma

Phase 2

Completed

Conditions: Glioma
Astrocytoma
Oligodendroglioma

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00165360

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Phase 2

Completed

Conditions: Neuroblastoma
Ewings Sarcoma
Non-rhabdomyosarcoma Soft Tissue Sarcoma

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165139

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Mantle Irradiation for Hodgkin's Disease

Phase 2

Completed

Conditions: Hodgkin's Disease

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00165269

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Treatment of Childhood Acute Lymphoblastic Leukemia

Phase 3

Terminated

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 491

Registration Number: NCT00165087

Locations: 🇺🇸
Ochsner Clinic, New Orleans, Louisiana, United States
🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇺🇸
Maine Medical Center, Lewiston, Maine, United States

and more 7 locations

Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer

Not Applicable

Completed

Conditions: Malignant Tumors
Subcutaneous Tumors
Lymph Node Tumors

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00165100

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma

Phase 2

Completed

Conditions: Colorectal Adenocarcinoma

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00165217

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy